Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidylprolyl isomerase A pseudogene 70 (PPIAP70) is a genomic sequence in humans that resembles the peptidylprolyl isomerase A (PPIA/cyclophilin A) gene but does not produce a functional protein[1]. It is classified as a pseudogene, meaning it arose through gene duplication or mutation and has lost its protein-coding potential. PPIAP70 is not considered a therapeutic target, receptor, enzyme, or relevant biomarker, but may be studied for its genomic context or potential regulatory roles common to some pseudogenes. There is no evidence for its direct involvement in drug interactions, molecular mechanisms, disease association, or clinical safety concerns. If a functional or therapeutic target was intended by searching for PPIAP70, the correct target should be Peptidylprolyl isomerase A (PPIA), also known as cyclophilin A, which is a well-studied protein-coding gene and drug target, notably for cyclosporin A[2][4][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidylprolyl isomerase A pseudogene 70 (PPIAP70).